pVXc-​486

pVXc-486 is an orally active and potent phosphate prodrug of VXc-486. pVXc-486 has potent bactericidal activities in vivo[1].

Research Areas >> Infection

Signaling Pathways >> Anti-infection >> Bacterial

pVXc-486 (oral gavage; 10, 30, 100 mg/kg; once per day; 5 times per week for 4 weeks) reduces the mycobacterial burden in a model of chronic tuberculosis infection in mice[1]. pVXc-486 (oral; 100 mg/kg; once per day; 5 days per week, for 8 weeks) improves the bactericidal activities of antimycobacterial drugs[1]. Animal Model: Six-week old female BALB/c and C57BL/6 mice uninfected or M. tuberculosis-infected (Erdman)[1] Dosage: 10, 30, 100 mg/kg Administration: Oral gavage; 5 times per week for 4 weeks Result: Reduced the mycobacterial burden in a model of chronic tuberculosis infection in mice.

[1]. Locher CP, et al. A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections.Antimicrob Agents Chemother. 2015 Mar;59(3):1455-65.